Focus switches from plasma to Vifor as CSL closes in on takeover

CSL shares are down 10 per cent year-to-date, but stock watchers see growth ahead for the listed biotech giant on the horizon.

Brisbane Times – Business

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Business